Merck KGaA Moderates New Drug Sales Ambitions For 2022
Raises Financial Guidance For 2021
Merck KGaA has narrowed its 2022 sales forecasts for its newly launched pharmaceuticals because of the COVID-19 pandemic, but still expects strong growth from these products and from products and services in its process solutions and electronic businesses.
You may also be interested in...
The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.